Published on 19/11/2025

How to Design ICFs, Assent & Short Forms That Aligns With GCP, ICH and Regulatory Guidance

Introduction to Informed Consent Forms (ICFs)

Informed Consent Forms (ICFs) are critical documents in clinical trials, serving as a primary means of communication between researchers and participants. These documents outline the purpose, risks, and benefits of research protocols while ensuring compliance with Good Clinical Practice (GCP) and regulatory standards set forth by international authorities like the FDA, EMA, and MHRA. The complexities involved in drafting these documents require a meticulous approach to align with guidelines while remaining comprehensible to participants.

This tutorial aims to provide a structured step-by-step guide for clinical operations, regulatory affairs, and medical affairs professionals on designing effective ICFs, assent forms, and short forms. Through this guidance, professionals can ensure that their documents meet regulatory requirements and contribute to ethical clinical practice, especially relevant for clinical trials such as non small cell lung cancer clinical trials, Aegean clinical trial, or Mariposa clinical trial.

Understanding Regulatory Frameworks for ICFs

The regulatory landscape for ICFs requires an understanding of various guidelines and regulations, such as the International Conference on Harmonisation (ICH) E6 Guideline for Good Clinical Practice, local regulations, and specific sponsor requirements. Each of these frameworks informs the essential elements that must be included in an ICF.

Primary Regulatory Guidelines

• FDA Regulations (21 CFR Part 50): details the informed consent process and outlines criteria for consent validity.
• EMA Guidelines: emphasizes the importance of clearly outlining the trial’s purpose and procedures to ensure participant understanding.
• ICH E6 (R2): includes comprehensive guidance on the necessity for ICFs to facilitate informed decision-making.
• MHRA Regulations: address the ethical principles involved in the informed consent process, focusing on participant rights and welfare.

To align ICFs with these regulations, it’s imperative to incorporate elements such as contact information, study objectives, eligibility criteria, and details on risks and benefits. Additionally, notes on how the data will be protected and used should be transparently communicated.

Steps for Designing Effective ICFs

The design of an ICF must be structured yet flexible enough to accommodate the complexities of various trials. Below, we provide a systematic approach for drafting ICFs that complies with both regulatory and ethical requirements.

Step 1: Define the Purpose and Objectives

The initial step in drafting an ICF is to clearly define the purpose of the clinical trial, including specific research objectives. This information serves not only to inform potential participants but also provides context for the rest of the document. Make sure to express the relevance of the study, particularly in specialized areas like non small cell lung cancer clinical trials.

Step 2: Identify the Target Audience

Understanding the demographics of the potential participants is crucial. This includes factors such as age, ethnicity, cultural background, and cognitive abilities. Establishing a clear understanding of the audience will guide the language and tone of the ICF. For example, ICFs for minors will need assent forms tailored to their understanding, and language must be simplified for populations with lower health literacy.

Step 3: Develop Clear and Concise Content

Using plain language is essential in ICF writing. Avoid medical jargon and complex terminology unless necessary, and always provide definitions for any technical terms included. Each section should be broken down into comprehensible parts:

• Trial Overview: Briefly describe the trial, its scientific rationale, and what participants can expect.
• Procedures: Clearly lay out the procedures participants will undergo, including any tests and interventions.
• Risks and Benefits: Explicitly state the risks, discomforts, and potential benefits of participation. Factors such as the potential for unknown side effects of investigational drugs should be highlighted, particularly in trials involving new therapies.
• Confidentiality: Assure participants that their data will be protected in accordance with data protection regulations such as GDPR in the UK and EU.

Step 4: Include Required Elements

Regulatory guidelines specify numerous elements that must be included in the ICF. According to ICH E6 (R2) and relevant sections from the FDA and EMA, the following components are essential:

• Informed nature of participation, including voluntary involvement.
• A description of the trial, including any deviations from standard treatments.
• Information regarding compensation and treatment for injury.
• Contact details for trial representatives who can be approached for questions or concerns.
• Details of what happens if the participant chooses to withdraw from the study.

Step 5: Pilot Test the ICF

Conducting a pilot test of the ICF with a small group representative of the target population can provide feedback on clarity and understandability. This step ensures that the document resonates with participants and can elucidate any areas of confusion that need refinement.

Assent Forms and Short Forms

In scenarios involving minors or individuals unable to provide full consent, assent forms play a crucial role. These forms are designed to communicate the basic components of the study to the participant and ensure they understand their involvement. In some cases, particularly in younger populations, short forms may be utilized alongside a verbal explanation of the study.

Designing Assent Forms

Assent forms should be age-appropriate and engaging. Use language and visuals that are relatable to the participant’s age group. The format can include:

• An overview of the study using age-appropriate analogies.
• Visual aids where applicable, such as diagrams about study procedures.
• Simple questions that gain feedback about their understanding of participation.

Short Forms: When and How to Use Them

Short forms are utilized in contexts where detailed ICFs may overwhelm the participant. They provide a brief summary of the essential elements and should be accompanied by an oral explanation from the investigator. Key considerations for short forms include:

• Ensure they satisfy all regulatory requirements, even in reduced format.
• Provide a detailed ICF to each participant once they provide consent, ensuring no information is omitted.

Compliance and Monitoring

Ensuring ongoing compliance with ICF regulations is a vital component of clinical trials. All ICFs and assent forms should be submitted for approval by an Institutional Review Board (IRB) or Ethics Committee prior to participant recruitment. Regular audits should also be conducted to verify that the informed consent process is being implemented correctly at trial sites.

Continuous Training for Site Management Organizations

Site Management Organizations (SMOs) that assist in the management of clinical trials must also focus on training staff on the importance of maintaining compliance with ICF regulations. Regular workshops can be beneficial in educating the clinical research team on updates to regulations, ensuring they stay abreast of crucial changes that affect the consent process.

Document Updates: Keeping Pace with Regulatory Changes

As regulations evolve, so too must ICFs. It is prudent to establish a review schedule for ICFs to align with regulatory amendments, particularly those issued by bodies such as the FDA or EMA. For example, new guidelines pertaining to data privacy or participant rights should trigger a review and update of documents to ensure compliance.

Conclusion: Best Practices for ICFs, Assent, and Short Forms

Designing ICFs, assent forms, and short forms is a pivotal part of the clinical trial process. It requires a comprehensive understanding of various regulatory frameworks, clear communication strategies, and a dedication to ethical practices. The steps outlined in this tutorial are intended to guide industry professionals through the complexities involved in drafting these key documents.

Ultimately, well-constructed ICFs serve to enhance participant understanding and welfare, ensuring informed participation throughout the clinical research process. Adhering to best practices, compliance standards, and ethical considerations not only safeguards participant rights but also fosters a culture of accountability and integrity within clinical operations.

By following this guide, professionals engaged in clinical trials—including those related to msa clinical trials—will be well-equipped to produce ICFs that support ethical research and align with global best practices. Regular engagement with regulatory bodies and continual education will also enhance the quality of consent processes in your clinical trials.